LONA:NASDAQ
LeonaBio Inc
5,75 USD
0,00%
(0,00) 1D
5,73 USD
arrow_downward
-0,35% (-0,020)bedtimeAfter hours
Closed: 9-окт., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LONA...
Open
5,82 USD
High
6,10 USD
Low
5,56 USD
Mkt. cap
54,17 млн
Avg. vol.
341,74 миң
Volume
66,68 миң
52-wk high
14,19 USD
52-wk low
2,21 USD
EPS
-19,72 USD
Beta
2,11
Shares outstanding
9,42 млн
No. of employees
19
Open
5,82 USD
High
6,10 USD
Low
5,56 USD
Mkt. cap
54,17 млн
Avg. vol.
341,74 миң
Volume
66,68 миң
52-wk high
14,19 USD
52-wk low
2,21 USD
EPS
-19,72 USD
Beta
2,11
Shares outstanding
9,42 млн
No. of employees
19
News stories
From web sources and news partners
Foreign Policy Journal
·
21 мүнөт мурун
AST SpaceMobile (NASDAQ: ASTS) Sits On $3.7 Billion In Liquidity As Analysts Project Tenfold Revenue Surge By 2028
Foreign Policy Journal
·
52 мүнөт мурун
SoundHound AI (NASDAQ: SOUN) Stock Hinges On Whether OASYS Can Deliver Sustained Growth
Yahoo Finance
·
2 саат мурун
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
24/7 Wall St.
·
16 саат мурун
Why "VOO and Chill" Lost Money for 8 Straight Years: What $100,000 in the S&P 500 Did From 2000 to 2008
Profile
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
About LeonaBio Inc
CEO-
Employees19
Founded2011
HeadquartersБотелл, Вашингтон, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websiteleonabio.com